Stockscreener 앱 받기
7.27
0.68%
-0.05
시간 외 거래:
7.35
0.08
+1.10%
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Scott Laverne Howell Net Worth (2026) - GuruFocus
Polymeropoulos Christos Vasilios Mihael Net Worth (2026) - GuruFocus
Vanda Pharmaceuticals (NASDAQ: VNDA) executive details stock, options and RSUs - Stock Titan
[Form 3] Vanda Pharmaceuticals Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update - MarketBeat
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
Vanda Pharmaceuticals opposes FDA drug review timeline proposal By Investing.com - Investing.com Australia
Vanda Pharmaceuticals (VNDA) Criticizes FDA Review Process Changes - GuruFocus
Market Leaders: Should I invest in Vanda Pharmaceuticals Inc before earnings2026 Top Gainers & Technical Confirmation Alerts - baoquankhu1.vn
Vanda Pharmaceuticals opposes FDA drug review timeline proposal - Investing.com
A 180-day drug review rule could stretch to 10-12 months under FDA plan - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on GLP-1 trial - Investing.com Australia
Vanda initiates trial of NEREUS for GLP-1 therapy side effects By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals (VNDA) Launches Thetis Trial for Vomiting Prevention - GuruFocus
Vanda initiates trial of NEREUS for GLP-1 therapy side effects - Investing.com Australia
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - Finviz
Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of Nereus™ For The Prevention Of Vomiting Induced By Glp-1 Receptor Agonists - TradingView — Track All Markets
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - Nasdaq
Options Flow: What is the target price for Vanda Pharmaceuticals Inc stockWeekly Trend Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Rate Cut: Is Vanda Pharmaceuticals Inc affected by consumer sentimentStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Downgrade Watch: Can Vanda Pharmaceuticals Inc ride the EV waveDip Buying & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Vanda Announces Resignation of Senior Legal Executive - The Globe and Mail
Vanda Pharmaceuticals executive Timothy Williams to resign as general counsel - Investing.com Australia
Timothy Williams resigns as Senior Vice President, General Counsel and Secretary at Vanda - TradingView — Track All Markets
Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026 - marketscreener.com
Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role - Stock Titan
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Aug Levels: Can Vanda Pharmaceuticals Inc ride the EV wavePortfolio Return Report & Low Risk Investment Opportunities - baoquankhu1.vn
Pullback Watch: Will Vanda Pharmaceuticals Inc outperform tech stocksRate Cut & Reliable Momentum Entry Alerts - baoquankhu1.vn
VNDA Technical Analysis & Stock Price Forecast - Intellectia AI
Vanguard disaggregates holdings; reports 0 shares of Vanda Pharmaceuticals (VNDA) - Stock Titan
Truist reiterates Vanda Pharmaceuticals stock rating after EMA decision By Investing.com - Investing.com Canada
Vanda Pharmaceuticals stock faces institutional dominance amid biotech sector volatility and retail - AD HOC NEWS
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Gastroparesis Pipeline 2026: FDA Updates, Therapy - openPR.com
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index - MarketScreener
Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com
If You Invested $1,000 in Vanda Pharma (VNDA) - Stock Titan
Insider Sell: Can Vanda Pharmaceuticals Inc ride the EV wave2026 PostEarnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals - timothysykes.com
Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks - StocksToTrade
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development - Intellectia AI
VNDA Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
What's going on with Vanda Pharma stock Tuesday? - MSN
Vanda Pharmaceuticals Faces Setbacks as CEO Mihael Polymeropoulos Sells Shares - StocksToTrade
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerat - GuruFocus
Vanda Pharmaceuticals urges FDA to accelerate move away from animal testing - Traders Union
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods - Bitget
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods – Company AnnouncementFT.com - Financial Times
2.69%
0.25%
자본화:
|
볼륨(24시간):